Clinical effects of intermittent, intravenous cyclophosphamide in severe systemic lupus erythematosus?

Nephron

Volumn 74, Issue 2, 1996, Pages 313-317

  Martinelli, Reinaldo ^a   Pereira, Luiz José C ^a   Santos, Elise Schaer C ^a   Rocha, Heonir ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Cyclophosphamide; Pulsotherapy; Severe SLE

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISONE; STEROID;

ADOLESCENT; ADULT; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NAUSEA; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; THROMBOCYTOPENIA; VERTIGO; VOMITING;

EID: 0029794436     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000189327     Document Type: Article

References (26)

1. Steinberg AD, Gourley MF. Klinman DM. Tsoko GC, Scott OE. Krieg AM: Systemic lupus erythematosus. Ann Intern Med 1991; 1 15:548-559.
2. Wallace DJ. Podell T, Weiner DPG, Klincn-berg JL. Forougesh S. Dubois EL: Systemic lupus erythematosus-survival patterns: Experience with 609 patients. JAMA 1981;245: 934-938.
3. Sturfcll G, Eskilsson J. Nived D. Truedason NG. Steinberg AD. Plotz PH. Decker JL: Cardiovascular disease in systemic lupus erythematosus: A study of 75 patients from a defined population. Medicine 1992:71:216-223.
4. Nived O. Sturfeld G. Wolheim F: Systemic lupus erythematosus and infections: A controlled and prospective study including an epidemiological group. Q J Med 1985:218:271-287.
5. Austin HA III. Klippel JH. Balow JE, Le Richs NG. Steinberg AD. Plotz PH. Decker JL: Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986:314:614-619.
6. Donadio JV Jr. Holloey KE. Ferguson RH, Ilstrup DM; Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978;299:1151-1155.
7. Felson DT. Anderson J: Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: Result of a pooled analysis. N Engl J Med 1984;31 1:1528-1533.
8. Steinberg AD. Steinberg SC: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide vcsus those treated with prednisone only. Arthritis Rheum 1991:34:945-950.
9. McCunc WJ. Golbus J. Zclder W. Bohlke P. Dunne R. Fox DA: Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988:318: 1423-1431.
10. Lehman TJA. Sherry DD, Wagncr-Wciner L. McCurdy DK. Emery HM. Magilary DA. Ko-valesky A: Intermittent inravenous cyclophosphamide therapy for lupus nephritis. J Pcdiatr 1989:114:1055-1060.
11. Boumpas DT. Austin HA III. Vaughan EM. Klippel JH. Steinberg AD, Yarboro CH. Balow JE: Controlled trial of pulse methylpredniso-lone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992:340:741-745.
12. Belmont HM. Storch M. Buvon J. Abramson S: New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: Efficacy in steroid unresponsive lupus nephritis. Lupus 1995:4:104- 108.
13. Boumpas DT. Yamada H. Patroncs NJ. Scott D, Klippel JH. Ralow IE: Pulse cyclophosphamide for severe neuropsychiatrie lupus. Q J Med 1991;81:975-984.
14. Neuwclt CM, Lacks S. Kaye BL. Fllman JB. Borenstein DG: Role of intravenous cyclophosphamide in the treatment of neuropsychiatrie systemic lupus erythematosus. Am J Med 1995;98:32-41.
15. Boumpas DT. Barez S. Klippel JH. Balow JE: Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1990:112:674-677.
16. Eiser AR. Shanies HM: Treatment of lupus interstitial lung disease w ith intravenous cyclophosphamide. Arthritis Rheum 1994:37:428- 431.
17. Donadio JV Jr. Glassock RJ: Immunosuppressive drug therapy in lupus nephritis. Am J Kidney Dis 1993;21:239-250.
18. Tan EM. Cohen AS. Preis JH. Masi AT. McSharc DJ. Rothfield NF. Sehaller JG. Talol N. Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982:25:1271-1277.
19. C'hurg J. Sobin LH: Renal Disease: Classification and Atlas of Glomerular Disease. Tokyo, lgaku-Shoin. 1982.
20. Donadío JV Jr. Holley KE, Ferguson RW, McDuffie FC: Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Ann Intern Med 1972:77:829-835.
21. Decker JL. Klippel JH. Plotz PH. Steinberg AD: Cyclophosphamide and azathioprine in lupus glomerulonephritis. Ann Intern Med 1975:83:606-615.
22. Donadío JV Jr. Holley KE. Ilstrup DM: Cytotoxic drug treatment of lupus nephritis. Am J Kidney Dis 1982;2(suppl): 178-181.
23. Ginzler EM. Diamond HS. Weiner M. Schlesinger M. Fries JP. Waisner C. Medsger TA Jr. Ziegler G. Klippel JH. Hadler NM. Albert DA. Hess AM. Spencer-Green G. Grayzel A, Worth D. Hohn BH. Barnet EV: A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables of predictors of prognosis. Arthritis Rheum 1982;25:601-611.
24. Esdaile JM, Levitón C. Federgreen W. Havslctt SP. Kashgarian M: The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: A study of 87 patients and review of the literature. Q j Med 1989:72:779-833.
25. Levine LA. Richie JP: Urological complications of cyclophosphamide. J Urol 1989:141: 1063-1069.
26. Hoffman GS. Kerr GS. Leavit RY, Hallahon MS. Lebovics RS. Travis WS. Rottem M. Fauci AS: Wcgncr granulomatosis: An analysis of 158 patients. Ann Intern Med 1992:116:488-498.